Last reviewed · How we verify

NCT05962424

HNC: Human Neural Circuits Electrophysiology During Cognition

Recruiting now Phase 1 Last updated 26 August 2025
What this trial tests

Phase 1 trial testing Ketamine Hydrochloride in Psychiatric Disorder in 120 participants. Currently enrolling.

Timeline
5 October 2023
Primary endpoint
1 September 2030
1 September 2030

Quick facts

Lead sponsorStanford University
PhasePhase 1
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposebasic science
Enrollment120
Start date5 October 2023
Primary completion1 September 2030
Estimated completion1 September 2030
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Stanford University

Who can join

18 and older, any sex, with Psychiatric Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to understand how ketamine brings about dissociative symptoms.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ketamine Hydrochloride

Trials testing the same drug.

Other recruiting trials for Psychiatric Disorder

Currently open trials in the same condition.

Other Stanford University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05962424.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing